Lipoprotein-Associated Phospholipase A 2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (7) , 1586-1593
- https://doi.org/10.1161/01.atv.0000222983.73369.c8
Abstract
Objectives— We sought to evaluate whether lipoprotein-associated phospholipase A2 (Lp-PLA2), an emerging marker of cardiovascular risk, is associated with prognosis in patients with coronary heart disease (CHD). Methods and Results— Plasma concentrations and activity of Lp-PLA2 were determined in 1051 patients aged 30 to 70 years with CHD who were followed for &4 years. A Cox proportional hazards model was used to determine the prognostic value of Lp-PLA2 after adjustment for various covariates, including markers of inflammation, renal function, and hemodynamic stress. In multivariable analyses, Lp-PLA2 mass and activity were strongly associated with cardiovascular events after controlling for traditional risk factors, severity of CHD, statin treatment, cystatin C, and N-terminal proBNP. The hazard ratio (HR) for recurrent events was 2.65 (95% confidence interval [CI], 1.47 to 4.76) for the top tertile of Lp-PLA2 mass compared with the bottom tertile and 2.40 (95% CI, 1.35 to 4.29) for Lp-PLA2 activity. After additional adjustment for low-density lipoprotein (LDL), the HRs were only moderately attenuated (mass: 2.09; 95% CI, 1.10 to 3.96; activity: 1.81; 95% CI, 0.94 to 3.49, respectively), but the latter was no longer statistically significant. Conclusions— Increased concentrations of Lp-PLA2 predict future cardiovascular events in patients with manifest CHD independent of a variety of potential risk factors including markers of inflammation, renal function, and hemodynamic stress. We found that lipoprotein-associated phospholipase A2 (Lp-PLA2) strongly predicts secondary cardiovascular events in patients with manifest coronary heart disease (CHD). In multivariable analysis, even including markers of inflammation, renal function, and hemodynamic stress, patients in the top tertile of the Lp-PLA2 mass and activity distribution showed &2-fold increased risk compared with those in the bottom tertile.Keywords
This publication has 28 references indexed in Scilit:
- Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- The effect of statin therapy on lipoprotein associated phospholipase A2 levelsAtherosclerosis, 2005
- Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic targetExpert Opinion on Investigational Drugs, 2005
- Association of Lipoprotein-Associated Phospholipase A 2 Mass and Activity With Calcified Coronary Plaque in Young AdultsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Cystatin CCirculation, 2004
- P2.66: A SAS‐macro package for development and validation of prognostic and diagnostic models based on the logistic regression modelBiometrical Journal, 2004
- The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-Associated phospholipase A2 for evaluation in manBioorganic & Medicinal Chemistry Letters, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Lipoprotein-associated PLA2 inhibition — a novel, non-lipid lowering strategy for atherosclerosis therapyIl Farmaco, 2001
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999